- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Eisai calls for immediate solution to CDF black hole
8 July 2016 • Author: Victoria White, Digital Content Producer
Eisai has expressed concern that patients in England and Wales will have to wait almost three years to access Lenvatinib due to a ‘black hole’ in the Cancer Drugs Fund (CDF) process.
Lenvatinib is not in the re-launched CDF and NICE guidance will not be published until at least 2018.
Lenvatinib is indicated for the treatment of adults with progressive locally advanced or metastatic, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (R-RAI).
Eisai is calling for a transitional arrangement to allow access for lenvatinib in advanced thyroid cancer, which is caught in limbo because it was not appraised before the CDF closed. At that time, lenvatinib did not qualify for NICE review, because it would have a low budget impact for the NHS. The company will consider all options, including possible legal action, to secure fair and equitable access for people with rarer cancers.
Eisai may consider its level of investment in the UK
Gary Hendler, Chairman and CEO Eisai EMEA, commented: “It is sad that patients living in England cannot access lenvatinib for advanced thyroid cancer which was developed and manufactured in this country. We believe there is an immediate solution, a transitional arrangement, to allow patients access to a treatment which has been disproportionately delayed by the changes in the CDF process. Eisai may be forced to consider its level of investment in the UK because it is unacceptable that drugs which are manufactured in England cannot be provided to people in England, without delays of many years.”
Kate Farnell MBE, Founder, Butterfly Thyroid Cancer Trust, commented: “People with advanced thyroid cancer do not have time to wait. This treatment is approved for use in Europe and the health system in England must provide access to lenvatinib as soon as possible.”
Lenvatinib was approved by the European Commission more than a year ago, in May 2015. The drug demonstrates an 18.3 months progression free survival versus 3.6 months for placebo in RAI-R differentiated thyroid cancer. Adverse events were hypertension, diarrhoea, fatigue, decreased appetite, decreased weight, and nausea.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics